iPS-ML-IFNa

iPS-ML-IFNa is an experimental cell-based immunotherapy consisting of human induced pluripotent stem (iPS) cell-derived myeloid cell lines (iPS-ML) that have been genetically engineered to produce and secrete interferon-alpha (IFN-α). Developed by researchers at Kumamoto University, this therapy utilizes the natural tumor-homing capabilities of myeloid cells to deliver IFN-α directly into the tumor microenvironment. This localized delivery is intended to activate antitumor immunity—specifically by promoting the differentiation of M1-type macrophages (marked by CD169 expression)—and to exert direct antiproliferative effects on cancer cells, such as metastatic melanoma, while avoiding the systemic toxicity associated with high-dose interferon administration. The iPS-ML platform allows for the large-scale production of standardized, macrophage-like cells with inherent tumor-homing capabilities.

Other names

human iPS cell-derived myeloid cell lines producing interferon-alphaiPS-ML-IFNα